When developing new therapies or medicines, there are many hurdles along the way to reaching the market. If you do, that is. Failure is lurking at every step. A drug candidate must be safe and show clinicial efficacy in patients without severe side effects. The risks are significant and so are the costs, but if a project is successful, the reward could be enormous. So, how can you assess the risks involved?
I det här avsnittet av Health & Wealth går Jesper Prior Larsen från Aixial Group – ett ledande bolag inom kliniska studier – igenom några avgörande aspekter att känna till innan man investerar i life science.
Se intervjun på biostock.se:
https://www.biostock.se/health-and-wealth/?utm_source=mail&utm_medium=mail&utm_campaign=hw&utm_id=hw
Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se